Warburg acquires Integration Health from Temasek and True North, hires new CEO

Global private equity firm Warburg Pincus has acquired Integrace Private Ltd, a domestic pharmaceutical company focused on orthopedics and gynecology, and hired Rehan Khan, former managing director of MSD and Abbott India, as managing director to drive the company’s next phase of growth.

While Warburg did not disclose details of the transaction, a person familiar with the matter said the value of the transaction was close to ₹1,000 million crowns. This is part of the investment firm’s plan to create a larger pharmaceutical platform that would include the potential acquisition of Koye Pharma and Maneesh Pharma, the person added, requesting anonymity.

Warburg declined to comment, while Koye and Maneesh did not respond to Mint’s emails as of press time.

As part of the transaction, existing shareholders True North and Temasek will fully exit their investments in Integration, Warburg said in a statement on Wednesday. Over the years, Integration has built a differentiated portfolio of more than 20 brands in attractive, fast-growing markets that cater to pain management, pregnancy and women’s health.

“The integration has built an exceptional foundation with a differentiated portfolio in orthopedics and gynaecology, a strong position in fast-growing therapeutic segments and trusted specialist relationships. This acquisition reflects our belief in therapy-focused, brand-led platforms and our ambition to build a scaled, market-leading pharma business in India,” said Pincus War Nema India Director.

Through its scientific marketing practices, Integration has a network of over 45,000 healthcare professionals across India, supported by a high-quality prescribing base of specialists across Orthopedics and Gynaecology.

“India’s pharmaceutical market is large and attractive with predictable long-term growth, particularly in women’s health and orthopedic therapies. With Warburg Pincus’ business-building experience and healthcare investment experience, we look forward to building a scaled platform for homegrown therapeutics formulations in India,” said Khan.

The deal comes at a time when India’s pharmaceutical market promises long-term growth opportunities for investors, driven by healthcare awareness, rising incomes and expanding access to quality care. Warburg Pincus believes the sector is well positioned to create scaled therapeutics platforms through strategic consolidation.

Warburg Pincus has been investing in India for three decades and over time has built one of the most established investment franchises in the country. The firm has partnered with leading pharmaceutical, medical technology, health services and life sciences businesses, including Metropolis, Laurus Labs, MedPlus, Meril Life Sciences and Appasamy Associates. The investment in Integration builds on this long-standing history of partnering with exceptional management teams to create scalable, industry-leading healthcare businesses.